Loading…
Combination Drug Development Incentive Act of 2013
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (11)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2015 · first_quarter · Pharmacy
Support H.R. 2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Support H.R. 2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; general issues related to health care reform; and all general issues related to the 21st Century Cures Initiative.
Client expense: $940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Copyright/Patent/Trademark
S. 1720, Patent Transparency and Improvements Act of 2013; H.R. 3309, Innovation Act; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 3116, MODDERN Cures Act of 2013; H.R. 2985, Combination Drug Development Incentive Act of 2013; various international intellectual property issues and proposals
Client expense: $1,520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
2014 · fourth_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Client expense: $650,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| PA |
2014 · fourth_quarter · Health Issues
Vaccine related issues and general biological issues, including biodefense and H.R. 2985, the Combination Drug Development Act of 2013.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Client expense: $750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Health Issues
Combination Drug Development Incentive Act of 2013 (HR 2985)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Client expense: $890,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2014 · fourth_quarter · Copyright/Patent/Trademark
H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisions H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2639, Patent Litigation and Innovation Act: Patent litigation provisions H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H.R. 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions H.R. 5233, Trade Secrets Protection Act of 2014: Provisions related to trade secrets H.R. 5750, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014: Provisions related to targeted IP incentives for new indications for rare diseases or conditions S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act: Patent litigation provisions S. 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S. 2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition S. 2267, Defend Trade Secrets Act of 2014: Provisions related to trade secrets S. 3004, Dormant Therapies Act of 2014: Provisions related to incentives to develop biopharmaceutical products Biopharmaceutical innovation and patent policy issues Biologics data protection issues Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act Issues related to biopharmaceutical economic incentives and intellectual property
Client expense: $3,960,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Medicare Payment Advisory Commission (MedPAC), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2014 · fourth_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and coldmedicines that contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Client expense: $840,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medical/Disease Research/Clinical Labs
Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient protection and Affordable Care Act. Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development. H.R. 4502, Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medical/Disease Research/Clinical Labs
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act. Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicinesthat contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
Client expense: $700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2014 · third_quarter · Health Issues
Combination Drug Development Incentive Act of 2013 (H.R. 2985, no Senate bill number yet).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Copyright/Patent/Trademark
H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisions H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H,R, 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions H.R. 5233, Trade Secrets Protection Act of 2014: Provisions related to trade secrets S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S.2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition S. 2267, Defend Trade Secrets Act of 2014: Provisions related to trade secrets Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act Issues related to biopharmaceutical economic incentives and intellectual property
Client expense: $3,680,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2014 · third_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Client expense: $880,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2014 · third_quarter · Health Issues
Vaccine related issues and general biological issues, including biodefense and H.R. 2985, the Combination Drug Development Incentive Act of 2013.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Copyright/Patent/Trademark
S. 1720, Patent Transparency and Improvements Act of 2013; H.R. 3309, Innovation Act; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 3116, MODDERN Cures Act of 2013; H.R. 2985, Combination Drug Development Incentive Act of 2013; various international intellectual property issues and proposals
Client expense: $1,600,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
2014 · third_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014."General issues related to the 21st Century Cures Initiative.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continuedover-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; general issues related to health care reform; and all general issues related to the 21st Century Cures Initiative.
Client expense: $940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient protection and Affordable Care Act. Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medical/Disease Research/Clinical Labs
Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Support H.R.2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Support H.R.2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Client expense: $655,940 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2014 · second_quarter · Copyright/Patent/Trademark
S. 1720, Patent Transparency and Improvements Act of 2013; H.R. 3309, Innovation Act; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 3116, MODDERN Cures Act of 2013; H.R. 2985, Combination Drug Development Incentive Act of 2013
Client expense: $880,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2014 · second_quarter · Health Issues
Vaccine related issues and general biological issues, including biodefense and H.R. 2985, the Combination Drug Development Incentive Act of 2013.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Copyright/Patent/Trademark
H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H,R, 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S.2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on trade secret issues Draft legislation on demand letters Issues related to biopharmaceutical economic incentives and intellectual property
Client expense: $4,190,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2014 · second_quarter · Health Issues
Combination Drug Development Incentive Act of 2013 (H.R. 2985, no Senate bill number yet).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014."
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act (ACT). Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medical/Disease Research/Clinical Labs
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"
Client expense: $720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · first_quarter · Copyright/Patent/Trademark
S. 1720, Patent Transparency and Improvements Act of 2013; H.R. 3309, Innovation Act; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 3116, MODDERN Cures Act of 2013; H.R. 2985, Combination Drug Development Incentive Act of 2013
Client expense: $1,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2014 · first_quarter · Health Issues
Vaccine related issues and general biological issues, including H.R. 2985, the Combination Drug Development Incentive Act of 2013.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Copyright/Patent/Trademark
H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013 H.R. 3116, MODDERN Cures Act of 2013 H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act of 2013: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013: Provisions related to patent settlements H.R. 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act of 2013: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act of 2013: Provisions related to patent litigation, demand letters and the patent system S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S. 2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2146, Patent Fee Integrity Act: Patent fee diversion prohibition Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on trade secret issues
Client expense: $4,680,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2014 · first_quarter · Health Issues
Combination Drug Development Incentive Act of 2013 (H.R. 2985).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Medical/Disease Research/Clinical Labs
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act. Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013"; and all provisions of HR1024 a "Medication Therapy Management Empowerment Act of 2013"; all provisions of HR3890 and S1932 "Better Care, Lower Cost Act"; issues related to thecontinued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; and awareness and education about Sanofi's Access to Medicines Program
Client expense: $1,570,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE